The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; AstraZeneca (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); MSD Oncology; Pfizer
Two-year survival with nivolumab in previously treated, advanced non-small cell lung cancer: A pooled analysis of real-world patients from France, Germany and Canada.
 
Martin Sebastian
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Mediolanum Farmaceutici; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Mediolanum Farmaceutici; MSD; Novartis; Pfizer; Roche; Takeda
Research Funding - Bristol-Myers Squibb
 
Clarisse Audigier-Valette
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche
Research Funding - Bristol-Myers Squibb
 
Charles Andrew Butts
Research Funding - AstraZeneca; Bristol-Myers Squibb; Merck
 
Didier Debieuvre
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Novartis; Pfizer; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chiesi (Inst); Chugai Pharma (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Novartis France; Roche; Roche; Roche
 
Adrien Dixmier
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Roche
Research Funding - Bristol-Myers Squibb
Other Relationship - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Roche
 
Andreas Gröschel
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche
Research Funding - Bristol-Myers Squibb
 
Sylvia Gutz
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Roche; Takeda
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche; Takeda
 
Rosalyn A. Juergens
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis Canada Pharmaceuticals Inc; Roche Canada
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Fusion Pharmaceuticals; Merck Sharp & Dohme; Novartis; Pfizer; Roche Canada; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Turnstone Bio (Inst)
 
Catherine Labbe
Honoraria - AstraZeneca; Bristol-Myers Squibb; Merck; Pfizer
Consulting or Advisory Role - Pfizer
Research Funding - AstraZeneca; Novartis; Roche; United Therapeutics
 
Denis Moro-Sibilot
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche; Takeda
Research Funding - Bristol-Myers Squibb
 
Maurice Perol
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Merck Sharp & Dohme; Pfizer; Roche; Takeda
 
Christian Schumann
No Relationships to Disclose
 
Ariadna Juarez-Garcia
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Khalid Lakhdari
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
John R. Penrod
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Filippa Pettersson
Employment - Bristol-Myers Squibb
 
Dorothee Reynaud
Employment - Bristol-Myers Squibb
 
Daniela Waldenberger
Employment - Bristol-Myers Squibb
 
Victoria Allan
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Fabrice Barlesi
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech